RT Journal Article
SR Electronic
T1 Sex-stratified genomic structural equation models of posttraumatic stress inform PTSD etiology
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.09.01.23294954
DO 10.1101/2023.09.01.23294954
A1 Moo-Choy, Ashley
A1 Stein, Murray B
A1 Gelernter, Joel
A1 Wendt, Frank R
YR 2023
UL http://medrxiv.org/content/early/2023/09/02/2023.09.01.23294954.abstract
AB Posttraumatic stress disorder (PTSD) affects 3.9%-5.6% of the worldwide population, with well-documented sex-related differences. While psychosocial and hormonal factors affecting sex differences in PTSD and posttraumatic stress (PTS) symptom etiology have been explored, there has been limited focus on genetic bases of these differences. Many symptom combinations may confer a PTSD diagnosis. We hypothesized that these symptom combinations have sex-specific patterns, the examination of which could inform etiological differences in PTSD genetics between males and females. To investigate this, we performed a sex-stratified multivariate genome-wide association study (GWAS) in unrelated UK Biobank (UKB) individuals of European ancestry. Using GWAS summary association data, genomic structural equation modeling was performed to generate sex-specific factor models using six indicator variables: trouble concentrating, feeling distant from others, irritability, disturbing thoughts, upset feelings, and avoidance of places/activities which remind the individual of a traumatic event. Models of male and female PTSD symptoms differed substantially (local standardized root mean square difference=3.12) and significantly (χ2(5)=28.03, p=3.6×10-5). Independent two-factor models best fit the data in both males and females; these factors were subjected to GWAS in each sex, revealing three genome-wide significant loci in females, mapping to SCAND3, WDPCP, and FAM120A. No genome-wide significant loci were identified in males. All four PTS factors (2 in males and 2 in females) were heritable (p<0.05): male PTS-f1 h2-SNP=1.85%, male PTS-f2 h2-SNP=1.47%, female PTS-f1 h2-SNP=3.87%, female PTS-f2 h2-SNP=3.53%. Male PTS-f1 was enriched for medication-related putative causal relationships (3.73-fold, p=0.032) while male PTS-f2 was enriched for body structure (2.84-fold, p=5.512×10-7) and cognitive (3.22-fold, p=0.009) putative causal relationships. In females, PTS-f1 was enriched for metabolic putative causal relationships (28.08-fold, p=0.035). By assessing the relationship between sex and PTSD symptoms, this study informs correlative and putatively causal etiological differences between males and females which support further investigation of sex differences in PTSD genetics.Competing Interest StatementDr. Stein has in the past 3 years received consulting income from Acadia Pharmaceuticals, Aptinyx, atai Life Sciences, BigHealth, Biogen, Bionomics, BioXcel Therapeutics, Boehringer Ingelheim, Clexio, Eisai, EmpowerPharm, Engrail Therapeutics, Janssen, Jazz Pharmaceuticals, NeuroTrauma Sciences, PureTech Health, Sage Therapeutics, Sumitomo Pharma, and Roche/Genentech. Dr. Stein has stock options in Oxeia Biopharmaceuticals and EpiVario. He has been paid for his editorial work on Depression and Anxiety (Editor-in-Chief), Biological Psychiatry (Deputy Editor), and UpToDate (Co-Editor-in-Chief for Psychiatry). Dr. Gelernter is paid for editorial work (Complex Psychiatry). The other authors have no competing interests to report. Funding StatementThis project is partially supported by funding from the University of Toronto Data Sciences Institute.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used GWAS summary data available for download from http://www.nealelab.is/uk-biobank.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesPTS factor summary statistics can be accessed via Zenodo: 10.5281/zenodo.8061505.